Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy.

We evaluated the biochemical recurrence (BCR) of prostate cancer patients treated by radical prostatectomy (RP) or radiotherapy (RT).

Patients who underwent RP or RT as primary definitive treatment from 2007 were enrolled for this study.

They were divided into two groups; the low-intermediate risk group and the high risk group according to the National Comprehensive Cancer Network guidelines. We compared differences such as age, prostate specific antigen, Gleason score, follow-up duration, clinical T staging, and BCR. Their BCR-free survival rates were analyzed.

A total of 165 patients were enrolled. There were 115 patients in the low-intermediate risk. Among them, 88 received RP and 27 underwent RT. BCR occurred in 9 of the RP patients (10. 2%) and 3 of the RT patients (11. 1%). For the high risk group, 50 patients were included. RP was performed in 25 patients and RT in 25 patients. BCR was observed in 4 of the RP patients (16%) and 12 of the RT patients (48%). There were no differences in BCR-free survival for the low-intermediate group (p=0. 765). For the high risk group, the RP group had a higher BCR free survival rate (p=0. 032).

No difference of BCR and BCR-free survival was seen in the low-intermediate risk group but lower BCR and better BCR-free survival were observed for patients that received RP in the high risk group. RP should be a more strongly considered option when deciding the treatment method for selected high risk patients.

Korean journal of urology. 2015 Oct 02 [Epub]

Dong Soo Kim, Seung Hyun Jeon, Sung-Goo Chang, Sang Hyub Lee

Department of Urology, Kyung Hee University School of Medicine, Seoul, Korea. , Department of Urology, Kyung Hee University School of Medicine, Seoul, Korea. , Department of Urology, Kyung Hee University School of Medicine, Seoul, Korea. , Department of Urology, Kyung Hee University School of Medicine, Seoul, Korea.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe